<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2176-6223</journal-id>
<journal-title><![CDATA[Revista Pan-Amazônica de Saúde]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Pan-Amaz Saude]]></abbrev-journal-title>
<issn>2176-6223</issn>
<publisher>
<publisher-name><![CDATA[Instituto Evandro Chagas. Secretaria de Vigilância em Saúde e Ambiente. Ministério da Saúde]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2176-62232020000100016</article-id>
<article-id pub-id-type="doi">10.5123/s2176-6223202000468</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Efetividade do tratamento com drogas antivirais de ação direta em pacientes com hepatite C atendidos em um centro de referência no estado do Pará, Brasil, de 2017 a 2019]]></article-title>
<article-title xml:lang="en"><![CDATA[Effectiveness of treatment with direct-acting antiviral drugs in patients with hepatitis C treated at a referral center in the Pará Sate, Brazil, from 2017 to 2019]]></article-title>
<article-title xml:lang="es"><![CDATA[Efectividad del tratamiento con drogas antivirales de acción directa en pacientes con hepatitis C atendidos en un centro de referencia en el estado de Pará, Brasil, de 2017 a 2019]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Borges Neto]]></surname>
<given-names><![CDATA[Francisco das Chagas]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Souza]]></surname>
<given-names><![CDATA[Madson Guilherme Lobato de]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Novaes]]></surname>
<given-names><![CDATA[Inah Camila do Rosário Barata]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silveira]]></surname>
<given-names><![CDATA[Vinícius Sousa da]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Nunes]]></surname>
<given-names><![CDATA[Mayara Pantoja]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Miranda]]></surname>
<given-names><![CDATA[Gabriel Castelo Branco Melo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moia]]></surname>
<given-names><![CDATA[Lizomar de Jesus Maués Pereira]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barbosa]]></surname>
<given-names><![CDATA[Maria Sílvia de Brito]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Miranda]]></surname>
<given-names><![CDATA[Esther Castello Branco Mello]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidade do Estado do Pará  ]]></institution>
<addr-line><![CDATA[Belém Pará]]></addr-line>
<country>Brazil</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidade Federal do Pará  ]]></institution>
<addr-line><![CDATA[Belém Pará]]></addr-line>
<country>Brazil</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Fundação Santa Casa de Misericórdia do Pará Grupo do Fígado ]]></institution>
<addr-line><![CDATA[Belém Pará]]></addr-line>
<country>Brazil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<volume>11</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_arttext&amp;pid=S2176-62232020000100016&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_abstract&amp;pid=S2176-62232020000100016&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iec.gov.br/scielo.php?script=sci_pdf&amp;pid=S2176-62232020000100016&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  OBJETIVO: Avaliar a efetividade e a tolerabilidade do tratamento da hepatite C com antivirais de ação direta em pacientes portadores de hepatite C crônica, atendidos no Ambulatório de Hepatologia da Fundação Santa Casa de Misericórdia do Pará, em Belém, estado do Pará, Brasil.  MATERIAIS E MÉTODOS: Estudo transversal, realizado com 305 pacientes em tratamento com sofosbuvir (SOF), daclatasvir (DAC) ou simeprevir (SMV) de maio de 2017 a março de 2019. Foram analisados os prontuários de 250 pacientes que concluíram o tratamento nesse período, dos quais foram avaliados dados demográficos e clínicos.  RESULTADOS: Observou-se predomínio do gênero masculino (50,40%), idade média de 61,21 anos e procedência de Belém (69,20). A maioria (54,00%) era portador de cirrose, e 40,80% relatou tratamento anterior. O genótipo 1 foi encontrado em 73,60%, e o genótipo 3, em 23,20% dos casos. O esquema de tratamento mais utilizado foi SOF, DAC e ribavirina (RBV) por 12 semanas. A taxa de resposta virológica sustentada (RVS) geral encontrada foi de 97,2%. Os não respondedores eram quatro do genótipo 3 e três do genótipo 1, sendo utilizados três esquemas com SOF+DAC+RBV por 12 semanas; dois esquemas com SOF+DAC por 12 semanas; um esquema com SOF+DAC por 24 semanas; e um esquema com SOF+SMV por 12 semanas.  CONCLUSÃO: Os resultados deste estudo mostraram uma população predominantemente urbana, masculina, a maioria de cirróticos, com predomínio do genótipo 1. Ressalta-se a boa tolerância e a elevada efetividade dos novos antivirais de ação direta, com uma taxa global de RVS de 97,2%.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  OBJECTIVE: To evaluate the effectiveness and tolerability of treating hepatitis C with direct-acting antivirals in patients with chronic hepatitis C treated at the Hepatology Outpatient Clinic of Fundação Santa Casa de Misericórdia do Pará, in Belém, Pará State, Brazil.  MATERIALS AND METHODS: Cross-sectional study with 305 patients treated with sofosbuvir (SOF), daclatasvir (DCV) or simeprevir (SMV) from May 2017 to March 2019. The medical records of 250 patients who completed treatment during this period were analyzed, of which demographic and clinical data were evaluated.  RESULTS: There was a predominance of males (50.40%), mean age of 61.21 years old and from Belém (69.20). Most of them (54.00%) had cirrhosis, and 40.80% reported previous treatment. Genotype 1 was found in 73.60%, and genotype 3 in 23.20% of cases. The standard treatment regimen was SOF, DCV and ribavirin (RBV) for 12 weeks. The rate of sustained virologic response (SVR) was 97.2%. n Four non-responders from genotype 3 and three from genotype 1, using three schemes with SOF+DCV+RBV for 12 weeks; two regimens with SOF+DCV for 12 weeks; a SOF+DCV regimen for 24 weeks; and a regimen with SOF+SMV for 12 weeks.  CONCLUSION: The results of this study showed a predominantly urban population, most of them were men and cirrhotic, with a predominance of genotype 1. It is important to notice the good tolerance and high effectiveness of the new direct-acting antivirals with an overall SVR rate of 97.2%.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  OBJETIVO: Evaluar la efectividad y la tolerabilidad del tratamiento de la hepatitis C con antivirales de acción directa en pacientes portadores de hepatitis C crónica, atendidos en el Ambulatorio de Hepatología de la Fundación Santa Casa de Misericordia de Pará, en Belém, estado de Pará, Brasil.  MATERIALES Y MÉTODOS: Estudio transversal, realizado con 305 pacientes en tratamiento con sofosbuvir (SOF), daclatasvir (DAC) o simeprevir (SMV) de mayo de 2017 a marzo de 2019. Se analizaron las historias clínicas de 250 pacientes que concluyeron el tratamiento en ese período, de las cuales se evaluaron datos demográficos y clínicos.  RESULTADOS: Predominó el género masculino (50,40%), edad media de 61,21 años y procedentes de Belém (69,20). La mayoría (54,00%) tenía cirrosis y el 40,80% informó tratamiento previo. El genotipo 1 se encontró en el 73,60%, y el genotipo 3, en el 23,20% de los casos. El régimen de tratamiento más utilizado fue SOF, DAC y ribavirina (RBV) durante 12 semanas. La tasa de respuesta virológica global (RVS) encontrada fue del 97,2%. Los no respondedores fueron cuatro del genotipo 3 y tres del genotipo 1, y se utilizaron tres esquemas con SOF+DAC+RBV durante 12 semanas; dos esquemas con SOF+DAC durante 12 semanas; un esquema con SOF+DAC durante 24 semanas; y un esquema con SOF+SMV durante 12 semanas.  CONCLUSIÓN: Los resultados de este estudio mostraron una población masculina predominantemente urbana, la mayoría de los cuales eran cirróticos, con predominio del genotipo 1. Se enfatiza la buena tolerancia y la alta efectividad de los nuevos antivirales de acción directa con una tasa general de RVS del 97,2%.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Hepatite C Crônica]]></kwd>
<kwd lng="pt"><![CDATA[Antivirais]]></kwd>
<kwd lng="pt"><![CDATA[Sofosbuvir]]></kwd>
<kwd lng="pt"><![CDATA[Simeprevir]]></kwd>
<kwd lng="pt"><![CDATA[Ribavirina]]></kwd>
<kwd lng="pt"><![CDATA[Combinação de Medicamentos]]></kwd>
<kwd lng="en"><![CDATA[Chronic Hepatitis C]]></kwd>
<kwd lng="en"><![CDATA[Antivirals]]></kwd>
<kwd lng="en"><![CDATA[Sofosbuvir]]></kwd>
<kwd lng="en"><![CDATA[Simeprevir]]></kwd>
<kwd lng="en"><![CDATA[Ribavirin]]></kwd>
<kwd lng="en"><![CDATA[Combination of Drugs]]></kwd>
<kwd lng="es"><![CDATA[Hepatitis C Crónica]]></kwd>
<kwd lng="es"><![CDATA[Antivirales]]></kwd>
<kwd lng="es"><![CDATA[Sofosbuvir]]></kwd>
<kwd lng="es"><![CDATA[Simeprevir]]></kwd>
<kwd lng="es"><![CDATA[Ribavirina]]></kwd>
<kwd lng="es"><![CDATA[Combinación de medicamentos]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Hepatitis C: fact sheets]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<collab>Ministério da Saúde (BR). Secretaria de Vigilância em Saúde</collab>
<article-title xml:lang=""><![CDATA[Hepatites virais 2019]]></article-title>
<source><![CDATA[Bol Epidemiol]]></source>
<year>2019</year>
<volume>50</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1-71</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Lo]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hepatitis C virus: virology, diagnosis and treatment]]></article-title>
<source><![CDATA[World J Hepatol]]></source>
<year>2015</year>
<volume>7</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1377-89</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coelho]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<source><![CDATA[Progressos terapêuticos na hepatite C]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Porto, PT ]]></publisher-loc>
<publisher-name><![CDATA[Universidade do Porto, Faculdade de Medicina]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mello]]></surname>
<given-names><![CDATA[CEB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamento da hepatite crônica pelo vírus C: novas perspectivas]]></article-title>
<source><![CDATA[J Bras Med]]></source>
<year>2014</year>
<volume>102</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>23-32</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lanini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mammone]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Puro]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Girardi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bruzzi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ippolito]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia: a frequentist meta-analysis approach]]></article-title>
<source><![CDATA[New Microbiol]]></source>
<year>2014</year>
<volume>37</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>263-76</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Islam]]></surname>
<given-names><![CDATA[MMSU]]></given-names>
</name>
<name>
<surname><![CDATA[Sarker]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Rahman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Uddin]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Rahman]]></surname>
<given-names><![CDATA[ATMA]]></given-names>
</name>
<name>
<surname><![CDATA[Biswas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of hepatitis C virus infection - new era has been started]]></article-title>
<source><![CDATA[Faridpur Med Coll J]]></source>
<year>2014</year>
<volume>9</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>92-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR). Secretaria de Vigilância em Saúde. Departamento de Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis, do HIV/Aids e das Hepatites Virais</collab>
<source><![CDATA[Protocolo clínico e diretrizes terapêuticas para hepatite C e coinfecções]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR). Secretaria de Vigilância em Saúde. Departamento de DST, Aids e Hepatites Virais</collab>
<source><![CDATA[Protocolo clínico e diretrizes terapêuticas para hepatite C e coinfecções]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR). Secretaria de Vigilância em Saúde. Departamento de DST, Aids e Hepatites Virais</collab>
<source><![CDATA[Protocolo clínico e diretrizes terapêuticas para hepatite C e coinfecções]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lawitz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sulkowski]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Ghalib]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez-Torres]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Younossi]]></surname>
<given-names><![CDATA[ZM]]></given-names>
</name>
<name>
<surname><![CDATA[Corregidor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2014</year>
<volume>384</volume>
<numero>9956</numero>
<issue>9956</issue>
<page-range>1756-65</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kwo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gitlin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Nahass]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bernstein]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Etzkorn]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Rojter]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study]]></article-title>
<source><![CDATA[Hepatology]]></source>
<year>2016</year>
<volume>64</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>370-80</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
<name>
<surname><![CDATA[Borba]]></surname>
<given-names><![CDATA[HHL]]></given-names>
</name>
<name>
<surname><![CDATA[Wiens]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pedroso]]></surname>
<given-names><![CDATA[MLA]]></given-names>
</name>
<name>
<surname><![CDATA[Radunz]]></surname>
<given-names><![CDATA[VFC]]></given-names>
</name>
<name>
<surname><![CDATA[Ivantes]]></surname>
<given-names><![CDATA[CAP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil]]></article-title>
<source><![CDATA[Braz J Infect Dis]]></source>
<year>2018</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>186-92</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holzmann]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Tovo]]></surname>
<given-names><![CDATA[CV]]></given-names>
</name>
<name>
<surname><![CDATA[Minmé]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Leal]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Kliemann]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Ubirajara]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil]]></article-title>
<source><![CDATA[Braz J Infect Dis]]></source>
<year>2018</year>
<volume>22</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>317-22</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molinar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Biff]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Bez]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perfil epidemiológico e resposta virológica sustentada de pacientes com hepatite C crônica em resposta ao tratamento com os novos antivirais de ação direta em dois serviços de referência do extremo sul catarinense]]></article-title>
<source><![CDATA[Arq Catarin Med]]></source>
<year>2019</year>
<volume>48</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>10-21</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rolim]]></surname>
<given-names><![CDATA[FE]]></given-names>
</name>
<name>
<surname><![CDATA[Braga]]></surname>
<given-names><![CDATA[LLBC]]></given-names>
</name>
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[JMC]]></given-names>
</name>
<name>
<surname><![CDATA[Mello]]></surname>
<given-names><![CDATA[FSF]]></given-names>
</name>
<name>
<surname><![CDATA[Pinho]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Hyppolito]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hepatite crônica pelo vírus C: avaliação da resposta virológica ao tratamento com os novos antivirais de ação direta]]></article-title>
<source><![CDATA[Rev Med UFC]]></source>
<year>2018</year>
<volume>58</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>8-12</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Azevedo]]></surname>
<given-names><![CDATA[DAF]]></given-names>
</name>
</person-group>
<source><![CDATA[Tratamento de hepatite C crônica com drogas antivirais de ação direta de segunda geração: Sofosbuvir, Simeprevir, Daclatasvir - resposta virológica sustentada no ambulatório de doenças do fígado do Hospital Universitário Gaffrée e Guinle]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Rio de Janeiro, RJ ]]></publisher-loc>
<publisher-name><![CDATA[Universidade Federal do Estado do Rio de Janeiro]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheinquer]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Coelho]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Aires]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Quintela]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Lobato]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Medeiros Filho]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New direct action antivirals containing regimes to treat patients with hepatitis C chronic infection: first results from a national real-world registry of the Brazilian Hepatology Society]]></article-title>
<source><![CDATA[J Hepatol]]></source>
<year>2017</year>
<volume>66</volume>
<numero>^s1 Suppl</numero>
<issue>^s1 Suppl</issue>
<supplement>1 Suppl</supplement>
<page-range>S508</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campiotto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pinho]]></surname>
<given-names><![CDATA[JRR]]></given-names>
</name>
<name>
<surname><![CDATA[Carrilho]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Da Silva]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Souto]]></surname>
<given-names><![CDATA[FJD]]></given-names>
</name>
<name>
<surname><![CDATA[Spinelli]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Geographic distribution of hepatitis C virus genotypes in Brazil]]></article-title>
<source><![CDATA[Braz J Med Biol Res]]></source>
<year>2005</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>41-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lawitz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mangia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wyles]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez-Torres]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hassanein]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Gordon]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sofosbuvir for previously untreated chronic hepatitis C infection]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2013</year>
<volume>368</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1878-87</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacobson]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Gordon]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Kowdley]]></surname>
<given-names><![CDATA[KV]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshida]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez-Torres]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sulkowski]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2013</year>
<volume>368</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1867-77</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nelson]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Lalezari]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Lawitz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pockros]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gitlin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study]]></article-title>
<source><![CDATA[Hepatology]]></source>
<year>2015</year>
<volume>61</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1127-35</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sulkowski]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Gardiner]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez-Torres]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Reddy]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Hassanein]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobson]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>370</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>211-21</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Medeiros]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Salviato]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[do Rosário]]></surname>
<given-names><![CDATA[NF]]></given-names>
</name>
<name>
<surname><![CDATA[Saraiva]]></surname>
<given-names><![CDATA[GDN]]></given-names>
</name>
<name>
<surname><![CDATA[Esberard]]></surname>
<given-names><![CDATA[EBC]]></given-names>
</name>
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience]]></article-title>
<source><![CDATA[Int J Clin Pharm]]></source>
<year>2017</year>
<volume>39</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1304-11</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="book">
<collab>Ministério da Saúde (BR). Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Comissão Nacional de Incorporação de Tecnologias no SUS</collab>
<source><![CDATA[Simeprevir para o tratamento da hepatite C]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Brasília ]]></publisher-loc>
<publisher-name><![CDATA[Ministério da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Global health sector strategy on viral hepatitis 2016-2021 [Internet]]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Genebra ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Global hepatitis report, 2017 [Internet]]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Genebra ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Combating hepatitis B and C to reach elimination by 2030 [Internet]]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Genebra ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohn]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Amorosa]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Lemoine]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Simplified diagnostic monitoring for hepatitis C, in the new era of direct-acting antiviral treatment]]></article-title>
<source><![CDATA[Curr Opin HIV AIDS]]></source>
<year>2015</year>
<volume>10</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>369-73</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
